In the News

Press & Media

Sleepaxa in the news.

Press coverage, public records and verifiable identifiers for Sleepaxa Private Limited, India’s first photobiological eyewear company, and its founder Suraj Dubey. Every link opens on the publisher’s or registry’s own site. Last updated 13 October 2026.

2023Founded · Surat, Gujarat
2 + 4Granted patents + pending
1 + 9PubMed-indexed review + open reports
DPIITRecognised · CTRI-registered study
As featured in The Times of India Business · India Business ·

“India’s Emerging Business Leaders Building a Better Tomorrow”

Sleepaxa and founder Suraj Dubey, Senior Optometrist, featured in The Times of India, 12 October 2026.

Read the feature

Coverage timeline

  • India’s Emerging Business Leaders Building a Better Tomorrow

    Business · India Business. Feature on Sleepaxa and founder Suraj Dubey.

  • India’s First Dual-Band Light Attenuation Lens Patent

    Optical-trade coverage of Indian Patent No. 587746, “An optical lens with dual-band selective light attenuation” — the technology behind NeuroCalm FLX+™. Described as believed to be the first Indian patent in the dual-band photobiological eyewear category.

  • Sleepaxa unveils revolutionary sleep and migraine glasses, a first in the country

    Launch announcement via Asian News International, syndicated across national outlets:

    Business Standard ThePrint ZEE5 LatestLY Reader Stuff Daily Gossip Online

On the public record

Entity & registry profiles

For journalists · boilerplate

Short (50 words)

Sleepaxa Private Limited (Surat, 2023) is India’s first photobiological eyewear company. It designs wavelength-selective lenses for evening screen use, circadian support and light sensitivity, holds two granted Indian patents, publishes PubMed-indexed research through its division Acieon Labs, and is DPIIT-recognised with a CTRI-registered clinical study.

Standard (100 words)

Sleepaxa Private Limited, incorporated in August 2023 in Surat, Gujarat, is India’s first photobiological eyewear company. Rather than generic blue-light blocking, it engineers lenses that attenuate specific wavelength bands tied to melanopsin and ipRGC signalling while preserving daytime visual comfort. The company holds two granted Indian patents — IN 587746 (NeuroCalm FLX+™, dual-band selective light attenuation) and IN 597482 (Circadian560™, multi-component chromophore lens) — with four further applications pending. Its research and intellectual-property division, Acieon Labs, publishes open-access technical reports and a PubMed-indexed narrative review. Sleepaxa is DPIIT-recognised and has a CTRI-registered clinical study.

Founder

Suraj Dubey, Founder & CEO, is a Senior Optometrist with more than ten years of clinical experience. Before founding Sleepaxa he ran his own optometry practice from 2017, personally conducting over 10,000 eye examinations. He is the named inventor on the company’s patent portfolio, Head of Research at Acieon Labs, and first author of its PubMed-indexed review (ORCID 0009-0003-7510-9254). He publishes on light science at @surajphotobiology.

Media & partnership enquiries: connect@sleepaxa.com · +91 96240 01789
Research, patents and publications: acieon.com · The Science Vault · About Sleepaxa

Frequently asked by reporters

Is Sleepaxa really India’s first photobiological eyewear company?

Sleepaxa positions itself as India’s first photobiological eyewear company — eyewear engineered around specific wavelength bands and non-visual photoreception (melanopsin/ipRGC pathways) rather than broad blue-light tinting. Its October 2023 launch was reported by ANI as a first in the country, and VisionPlus Magazine (April 2026) described its dual-band lens patent as believed to be the first in that category in India.

What patents does Sleepaxa hold?

Two granted Indian patents: IN 587746, “An optical lens with dual-band selective light attenuation” (NeuroCalm FLX+™, application 202521094370, all 10 claims allowed), and IN 597482, a multi-component chromophore lens (Circadian560™). Four further applications are pending across six inventions. The full register, with official application numbers, is maintained at acieon.com/patents.

Is the research peer-reviewed?

One work is peer-reviewed and PubMed-indexed: a narrative review published in Cureus on 27 July 2026 (DOI 10.7759/cureus.113484; PMID 42524168), first-authored by Suraj Dubey with co-authors Nandhini Elango, Lanisha Blessy Coelho and Dr. Monica Chaudhry. The nine Acieon Labs technical reports on Zenodo are open-access and DOI-registered but not peer-reviewed; the company lists them for transparency and does not describe them as peer-reviewed.

Who is Suraj Dubey?

Suraj Dubey is the Founder and CEO of Sleepaxa Private Limited and Head of Research at Acieon Labs. He is a Senior Optometrist with over ten years of clinical experience, the named inventor on the company’s patents, and first author of its PubMed-indexed review. ORCID 0009-0003-7510-9254. He was featured in The Times of India on 12 October 2026.

What is Acieon Labs and how does it relate to Sleepaxa?

Acieon Labs (acieon.com) is the research and intellectual-property division of Sleepaxa Private Limited. It publishes the science, patents and researcher disclosures; Sleepaxa is the product division that sells eyewear and handles consultation, support and fulfilment. The separation is deliberate so that research documentation is not marketing.

Are Sleepaxa glasses a medical device?

No. Sleepaxa eyewear is assistive visual-comfort eyewear and is not a medical device. Product pages and research pages carry this disclosure. Sleepaxa has a clinical study registered with the Clinical Trials Registry of India (CTRI/2024/07/070580).

How do I request an interview, images or a quote?

Email connect@sleepaxa.com or call +91 96240 01789. High-resolution product and founder images, spectral transmission data and patent certificates are available on request. For research or IP questions, contact Acieon Labs via acieon.com.

Assistive visual-comfort eyewear. Not a medical device. Not medical advice. Media logos and article content remain the property of their respective publishers.